Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study.
Clinical impact of ITCA 650, a novel drug-model GLP-1 receptor antagonist, in uncontrolled type 2 diabetes and a high base HbAsub>1c/sub> : The FREEDOM-1 HBL (High Baseline Study ).